Urinary Tract InfectionsNCT05573334
Vaginal Care System for Menopausal Women With Urinary Tract Infections
A study testing BioNourish in people with Urinary Tract Infections and Vaginal Flora Imbalance, run by Vaginal Biome Science at 1 site in United States.
Trial summary
Menopausal women have an increased risk of recurrent urinary tract infections. This is likely due in part to hormonal changes occurring during menopause. As estrogen falls, the vaginal microbiome shifts from a healthy one to a less healthy one. Read more about this study
- Who is it for?
- Ages Up to 89 years, women only
- Conditions the study is for
- Urinary Tract Infections, Vaginal Flora Imbalance
- What is being tested?
- BioNourish
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Jul 2023to 8 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 89 years
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Post-menopausal women who are in generally good health, including those with chronic conditions adequately controlled by common medications. Post-menopausal is defined as >12 months since last menstrual period. Menopause may be natural or induced due to surgical or medical intervention.
- History of at least 2 UTIs in the past six months, or three prior UTIs in the past year, documented in the medical record. At least one must be culture proven.
Who cannot join
- Immunosuppressed
- Known allergies to aloe vera or to other components of BioNourish®, Balance, or BiopHresh®
- Known vaginal infection other than bacterial vaginosis (BV) or yeast infection at time of screening
- Women who have needed changes to medical intervention or in-office procedures in the last 3 months
- Women who wear a pessary
- Women who use catheters regularly
- Women with an obstruction or neurogenic bladder causing incomplete bladder emptying.
Trial locations and contacts
1 site in 1 country.
United States1 site
Center for Urogynecology & Pelvic Reconstructive Surgery
Newark, Delaware, 19713
About this study
Official title: Effects of Flourish HEC Vaginal Care System in Menopausal Women With Recurrent Urinary Tract Infections
Menopausal women have an increased risk of recurrent urinary tract infections. This is likely due in part to hormonal changes occurring during menopause. As estrogen falls, the vaginal microbiome shifts from a healthy one to a less healthy one. Because the vagina is close to the urethra, this vaginal microbiome shift contributes to a loss of protection against urinary tract infections (UTIs). The investigators are asking whether improving the vaginal microbiome using an over-the-counter vaginal hygiene system can reduce frequency of recurrent UTI in menopausal women.
Read the detailed description
Urinary tract infections (UTIs) are caused by microorganisms that enter the urethra and cause inflammation. These infectious microbes can migrate up the urinary tract into the bladder, the ureters, and finally into the kidneys if untreated. UTIs ascending to the kidneys are responsible for up to 100,000 hospitalizations each year, and primarily occur in post-menopausal women or catheterized men. Infection of the urethra or bladder most frequently causes symptoms including frequent and intense urge to urinate, burning sensation during urination, cloudy or bloody urine, and pelvic pain. Infection that progresses to the kidneys most frequently causes symptoms including back or flank pain, fever, chills, and vomiting. The most common treatment for uncomplicated UTIs is oral antibiotics, which are usually effective but have undesirable side effects such as diarrhea and vaginal yeast infection and carry risks to vital organs, including the kidney itself. Repeated use of antibiotics is also the major cause of antibiotic resistance. Therefore, development of an alternative treatment or prevention strategy is desirable.
The microbiota of the urogenital tract is abnormal in female patients with recurrent UTI compared with that of healthy women. One known risk factor for UTIs is the loss of lactobacilli in the vaginal flora; physical proximity of the urethral orifice to the vaginal introitus explains the connection. Together, these data suggest there may be a role the vaginal microbiota, particularly lactobacilli, play in maintaining urogenital health and reducing the risk of UTI. The Flourish HEC Vaginal Care System is an over-the-counter vulvovaginal wellness system comprised of three products already commercially available that may help support the environment needed for the healthy microbes to thrive. ("HEC" designates hydroxyethylcellulose, a natural gelling ingredient used in this system, differentiating it from an earlier Flourish system which used aloe gel).
Normal premenopausal vaginal flora is lactobacilli dominant. Estrogen drives the maturation and thickening of the vaginal epithelium, including the production of large quantities of glycogen. Glycogen is metabolized to smaller units such as maltose, maltotriose, and dextrans, which serve as the fuel for lactobacilli. Lactobacilli maintain vaginal pH in the acidic range by producing lactic acid; this both supports the lactobacilli and keeps the growth of pathogenic bacteria at low levels. Most Lactobacillus spp., including those associated with the healthiest vaginal environments, produce racemic lactic acid. Lactobacilli also produce proteins with bactericidal activity which help to maintain their dominance. But the primary tool lactobacilli depend on to maintain their competitive advantage is the acidity they produce. Because of this circle of pH and lactobacilli levels, anything that alters the vaginal flora and/or changes the pH to a more basic environment will reduce vaginal lactobacilli levels and may increase the risk of UTI. This circle is especially difficult to break after menopause due to the loss of estrogen which leads to loss of fuel for lactobacilli.
Menopausal women with a history of recurrent UTI will be recruited to participate in a clinical trial to determine whether use of a vaginal hygiene system can reduce frequency of UTI. Women in the intervention group will use an over-the-counter kit for six months; these products are already available on the market. Changes in vaginal microbiome, changes in vaginal pH, changes in symptoms of genitourinary syndrome of menopause, and frequency of UTI over the six-month study will be assessed and compared to controls following routine care only.
- Conditions
- Urinary Tract Infections, Vaginal Flora Imbalance
- Being tested
- BioNourish
- Keywords
- Recurrent urinary tract infection, Vaginal microbiome, Probiotic, Lactobacillus
- Medical subject headings
- Urinary Tract Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BioNourishDevice
BioNourish is a 510k-cleared class II medical device that has been on the market for over two years. It is a vaginal moisturizing gel that is designed with pH, osmolality, and lactic acid levels that match those observed in healthy vaginas. It does not have an "active ingredient", but only provides moisture in a formula that is matched for physicochemical characteristics to healthy vaginal fluid.
| Study group | Role | What they receive |
|---|---|---|
| Routine Care | No intervention | The Routine Care arm is a control group receiving no study intervention. They receive whatever routine care is standard for the study PI's treatment of usual recurrent UTI patients, including antibiotics for active infections, estrogen and supplements for prevention of infection. |
| Flourish HEC | Experimental | The experimental (or intervention) arm uses 3 products in a vaginal hygiene system in addition to any routine care they would normally receive. These 3 products are a vulvar wash (for external use), a vaginal moisturizing gel (BioNourish), and a vaginal homeopathic suppository with probiotics.
The vulvar wash is used daily or as often as a participant bathes/showers. The vaginal moisturizing gel, which is formulated to match healthy vaginal secretions for pH, osmolality, and lactic acid levels, is used every day before bed.
The vaginal homeopathic suppository with probiotics is used every 3rd day before bed. This suppository contains native vaginal probiotic species associated with healthy vaginal microbiomes. Receives: Device: BioNourish |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in vaginal microbiome composition
The vaginal microbiome will be assessed using a whole-genome sequencing method at baseline, 3 months, and 6 months. Each measurement will be assigned to one of several "community state types" (CSTs). This outcome examines whether vaginal microbiome shifts from unhealth (CST IV) to intermediate (CST III) or healthy (CST I, II, or V) types over time. This is a three-way repeated measures analysis using study arm, time, and level of CST (healthy, intermediate, unhealthy) as factors.
Measured: Baseline to 3 and 6 months in a repeated measures assessment.
Change in vaginal pH
The vaginal pH will be assessed using a colorimetric paper strip at baseline, 3 months, and 6 months. This outcome examines numeric changes in pH over time. This is a three-way repeated measures analysis using study arm, time, and pH level as factors.
Measured: Baseline to 3 and 6 months in a repeated measures assessment.
Frequency of UTI
The mean number of UTIs experienced per participant during the 6-month study period will be compared between control and experimental arms using a Student's t-test.
Measured: 6 months duration of study
Secondary outcomes (1)
Frequency of UTI with estrogen-use covariate
The mean number of UTIs experienced per participant during the 6-month study period will be compared between control and experimental arms as in Outcome 3, adding estrogen usage (vaginal or systemic) as a factor in a two-way ANOVA.
Measured: 6 months duration of study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Oct 2022
- Study start10 Jul 2023
- Primary completion8 Dec 2025
- Study completion8 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Urinary Tract InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vaginal Biome Science
- Sponsor type
- University, hospital or other
- Collaborators
- ChristianaCare
- Responsible party
- Sponsor
- Investigators
- Helen Cohen, MS, RN, WHNP-BC, Principal investigator, ChristianaCare
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05573334
- Sponsor's protocol ID
- MUTI0822
- Status last verified
- Jan 2026
- First submitted
- 5 Oct 2022
- Last updated
- 28 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Flourish HEC Vaginal Care System in Menopausal Women With Recurrent Urinary Tract Infections
- ClinicalTrials.gov ID
- NCT05573334
- Acronym / sponsor ID
- MUTI0822
- Conditions
- Urinary Tract Infections, Vaginal Flora Imbalance
- Keywords
- Recurrent urinary tract infection, Vaginal microbiome, Probiotic, Lactobacillus
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Vaginal Biome ScienceUniversity, hospital or other
- Collaborators
- ChristianaCare
- Study start
- 10 Jul 2023 (actual)
- Primary completion
- 8 Dec 2025 (actual)
- Study completion
- 8 Dec 2025 (actual)
- First posted
- 10 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Menopausal women have an increased risk of recurrent urinary tract infections. This is likely due in part to hormonal changes occurring during menopause. As estrogen falls, the vaginal microbiome shifts from a healthy one to a less healthy one. Because the vagina is close to the urethra, this vaginal microbiome shift contributes to a loss of protection against urinary tract infections (UTIs). The investigators are asking whether improving the vaginal microbiome using an over-the-counter vaginal hygiene system can reduce frequency of recurrent UTI in menopausal women.
Detailed description
Urinary tract infections (UTIs) are caused by microorganisms that enter the urethra and cause inflammation. These infectious microbes can migrate up the urinary tract into the bladder, the ureters, and finally into the kidneys if untreated. UTIs ascending to the kidneys are responsible for up to 100,000 hospitalizations each year, and primarily occur in post-menopausal women or catheterized men. Infection of the urethra or bladder most frequently causes symptoms including frequent and intense urge to urinate, burning sensation during urination, cloudy or bloody urine, and pelvic pain. Infection that progresses to the kidneys most frequently causes symptoms including back or flank pain, fever, chills, and vomiting. The most common treatment for uncomplicated UTIs is oral antibiotics, which are usually effective but have undesirable side effects such as diarrhea and vaginal yeast infection and carry risks to vital organs, including the kidney itself. Repeated use of antibiotics is also the major cause of antibiotic resistance. Therefore, development of an alternative treatment or prevention strategy is desirable.
The microbiota of the urogenital tract is abnormal in female patients with recurrent UTI compared with that of healthy women. One known risk factor for UTIs is the loss of lactobacilli in the vaginal flora; physical proximity of the urethral orifice to the vaginal introitus explains the connection. Together, these data suggest there may be a role the vaginal microbiota, particularly lactobacilli, play in maintaining urogenital health and reducing the risk of UTI. The Flourish HEC Vaginal Care System is an over-the-counter vulvovaginal wellness system comprised of three products already commercially available that may help support the environment needed for the healthy microbes to thrive. ("HEC" designates hydroxyethylcellulose, a natural gelling ingredient used in this system, differentiating it from an earlier Flourish system which used aloe gel).
Normal premenopausal vaginal flora is lactobacilli dominant. Estrogen drives the maturation and thickening of the vaginal epithelium, including the production of large quantities of glycogen. Glycogen is metabolized to smaller units such as maltose, maltotriose, and dextrans, which serve as the fuel for lactobacilli. Lactobacilli maintain vaginal pH in the acidic range by producing lactic acid; this both supports the lactobacilli and keeps the growth of pathogenic bacteria at low levels. Most Lactobacillus spp., including those associated with the healthiest vaginal environments, produce racemic lactic acid. Lactobacilli also produce proteins with bactericidal activity which help to maintain their dominance. But the primary tool lactobacilli depend on to maintain their competitive advantage is the acidity they produce. Because of this circle of pH and lactobacilli levels, anything that alters the vaginal flora and/or changes the pH to a more basic environment will reduce vaginal lactobacilli levels and may increase the risk of UTI. This circle is especially difficult to break after menopause due to the loss of estrogen which leads to loss of fuel for lactobacilli.
Menopausal women with a history of recurrent UTI will be recruited to participate in a clinical trial to determine whether use of a vaginal hygiene system can reduce frequency of UTI. Women in the intervention group will use an over-the-counter kit for six months; these products are already available on the market. Changes in vaginal microbiome, changes in vaginal pH, changes in symptoms of genitourinary syndrome of menopause, and frequency of UTI over the six-month study will be assessed and compared to controls following routine care only.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Routine Care | No intervention | –The Routine Care arm is a control group receiving no study intervention. They receive whatever routine care is standard for the study PI's treatment of usual recurrent UTI patients, including antibiotics for active infections, estrogen and supplements for prevention of infection. |
| Flourish HEC | Experimental | Device: BioNourishThe experimental (or intervention) arm uses 3 products in a vaginal hygiene system in addition to any routine care they would normally receive. These 3 products are a vulvar wash (for external use), a vaginal moisturizing gel (BioNourish), and a vaginal homeopathic suppository with probiotics. The vulvar wash is used daily or as often as a participant bathes/showers. The vaginal moisturizing gel, which is formulated to match healthy vaginal secretions for pH, osmolality, and lactic acid levels, is used every day before bed. The vaginal homeopathic suppository with probiotics is used every 3rd day before bed. This suppository contains native vaginal probiotic species associated with healthy vaginal microbiomes. |
Who may qualify
- Ages
- Up to 89 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- Post-menopausal women who are in generally good health, including those with chronic conditions adequately controlled by common medications. Post-menopausal is defined as >12 months since last menstrual period. Menopause may be natural or induced due to surgical or medical intervention.
- History of at least 2 UTIs in the past six months, or three prior UTIs in the past year, documented in the medical record. At least one must be culture proven.
Key exclusion criteria (7 listed)
- Immunosuppressed
- Known allergies to aloe vera or to other components of BioNourish®, Balance, or BiopHresh®
- Known vaginal infection other than bacterial vaginosis (BV) or yeast infection at time of screening
- Women who have needed changes to medical intervention or in-office procedures in the last 3 months
- Women who wear a pessary
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BioNourishBioNourish is a 510k-cleared class II medical device that has been on the market for over two years. It is a vaginal moisturizing gel that is designed with pH, osmolality, and lactic acid levels that match those observed in healthy vaginas. It does not have an "active ingredient", but only provides moisture in a formula that is matched for physicochemical characteristics to healthy vaginal fluid. | Device | Flourish HEC |
Primary outcome
Change in vaginal microbiome composition
Time frame: Baseline to 3 and 6 months in a repeated measures assessment.
The vaginal microbiome will be assessed using a whole-genome sequencing method at baseline, 3 months, and 6 months. Each measurement will be assigned to one of several "community state types" (CSTs). This outcome examines whether vaginal microbiome shifts from unhealth (CST IV) to intermediate (CST III) or healthy (CST I, II, or V) types over time. This is a three-way repeated measures analysis using study arm, time, and level of CST (healthy, intermediate, unhealthy) as factors.
Change in vaginal pH
Time frame: Baseline to 3 and 6 months in a repeated measures assessment.
The vaginal pH will be assessed using a colorimetric paper strip at baseline, 3 months, and 6 months. This outcome examines numeric changes in pH over time. This is a three-way repeated measures analysis using study arm, time, and pH level as factors.
Frequency of UTI
Time frame: 6 months duration of study
The mean number of UTIs experienced per participant during the 6-month study period will be compared between control and experimental arms using a Student's t-test.
1 secondary outcome
Frequency of UTI with estrogen-use covariate
Time frame: 6 months duration of study
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Urinary Tract Infections
Recruiting
Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture
Urinary Tract Infections
Active, not recruitingObservational study
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
Complicated Urinary Tract Infection
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Recruiting
INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS
Drug Resistance, Microbial, Biomarkers
Not yet recruitingObservational study
Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)
Urinary Tract Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Helen Cohen, MS, RN, WHNP-BC principal investigator
ChristianaCare
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing BioNourish in people with Urinary Tract Infections and Vaginal Flora Imbalance, run by Vaginal Biome Science at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in vaginal microbiome composition (time frame: Baseline to 3 and 6 months in a repeated measures assessment.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2026.